Listed

Processa Pharmaceuticals, Inc.

PCSANasdaqCIK 1533743HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q3 FY2023
Operating income−$2.3m, Q2 FY2026
Net income−$3.3m, Q2 FY2026
Processa Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$k0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2023-11-13, accession 0001493152-23-040472. Derived: 9-month figure less the 6-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Cost of revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Gross profit$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Selling, general and administrative$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$k(2,168)Operating income, Q3 FY2023, three months to 2023-09-30−$2.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figure(2,469)Operating income, Q4 FY2023, three months to 2023-12-31−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-20, accession 0001641172-25-000070. Derived: 12-month figure less the 9-month figure.Report this figure(2,810)Operating income, Q1 FY2024, three months to 2024-03-31−$2.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001641172-25-009252.Report this figure(3,082)Operating income, Q2 FY2024, three months to 2024-06-30−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001493152-25-011685.Report this figure(3,425)Operating income, Q3 FY2024, three months to 2024-09-30−$3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure(2,735)Operating income, Q4 FY2024, three months to 2024-12-31−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001493152-26-011204. Derived: 12-month figure less the 9-month figure.Report this figure(2,847)Operating income, Q1 FY2025, three months to 2025-03-31−$2.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure(3,951)Operating income, Q2 FY2025, three months to 2025-06-30−$4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure(3,489)Operating income, Q3 FY2025, three months to 2025-09-30−$3.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure(3,702)Operating income, Q4 FY2025, three months to 2025-12-31−$3.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001493152-26-011204. Derived: 12-month figure less the 9-month figure.Report this figure(3,331)Operating income, Q1 FY2026, three months to 2026-03-31−$3.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure(2,336)Operating income, Q2 FY2026, three months to 2026-06-30−$2.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure
Interest expense$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(2,082)Net income, Q3 FY2023, three months to 2023-09-30−$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figure(2,405)Net income, Q4 FY2023, three months to 2023-12-31−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-20, accession 0001641172-25-000070. Derived: 12-month figure less the 9-month figure.Report this figure(2,726)Net income, Q1 FY2024, three months to 2024-03-31−$2.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure(3,010)Net income, Q2 FY2024, three months to 2024-06-30−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure(3,385)Net income, Q3 FY2024, three months to 2024-09-30−$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure(2,729)Net income, Q4 FY2024, three months to 2024-12-31−$2.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001493152-26-011204. Derived: 12-month figure less the 9-month figure.Report this figure(2,834)Net income, Q1 FY2025, three months to 2025-03-31−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure(3,934)Net income, Q2 FY2025, three months to 2025-06-30−$3.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure(3,437)Net income, Q3 FY2025, three months to 2025-09-30−$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure(3,359)Net income, Q4 FY2025, three months to 2025-12-31−$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001493152-26-011204. Derived: 12-month figure less the 9-month figure.Report this figure(3,377)Net income, Q1 FY2026, three months to 2026-03-31−$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure(3,265)Net income, Q2 FY2026, three months to 2026-06-30−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure
Diluted EPS$ per share(1.54)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figurenot reported(1.11)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001641172-25-009252.Report this figure(1.01)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$1.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001493152-25-011685.Report this figure(1.03)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figurenot reported(7.58)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$7.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure(6.26)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$6.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure(0.07)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figurenot reported(1.29)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure(1.19)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure
Basic EPS$ per share(1.54)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figurenot reported(1.11)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001641172-25-009252.Report this figure(1.01)Basic EPS, Q2 FY2024, three months to 2024-06-30−$1.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001493152-25-011685.Report this figure(1.03)Basic EPS, Q3 FY2024, three months to 2024-09-30−$1.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figurenot reported(7.58)Basic EPS, Q1 FY2025, three months to 2025-03-31−$7.58 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure(6.26)Basic EPS, Q2 FY2025, three months to 2025-06-30−$6.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure(0.07)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figurenot reported(1.29)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure(1.19)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure

Balance sheet

Cash and equivalents$196.3k, Q2 FY2026
Shareholders' equity−$317.3k, Q2 FY2026
Processa Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$k6,861Cash and equivalents, Q3 FY2023, at 2023-09-30$6.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0001493152-23-040472.Report this figure4,706Cash and equivalents, FY2023, at 2023-12-31$4.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-20, accession 0001641172-25-000070.Report this figure8,920Cash and equivalents, Q1 FY2024, at 2024-03-31$8.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-10, accession 0001493152-24-018648.Report this figure5,571Cash and equivalents, Q2 FY2024, at 2024-06-30$5.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-13, accession 0001493152-24-031622.Report this figure2,891Cash and equivalents, Q3 FY2024, at 2024-09-30$2.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figure1,191Cash and equivalents, FY2024, at 2024-12-31$1.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-18, accession 0001493152-26-011204.Report this figure2,897Cash and equivalents, Q1 FY2025, at 2025-03-31$2.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001641172-25-009252.Report this figure6,937Cash and equivalents, Q2 FY2025, at 2025-06-30$6.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001493152-25-011685.Report this figure6,308Cash and equivalents, Q3 FY2025, at 2025-09-30$6.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure5,537Cash and equivalents, FY2025, at 2025-12-31$5.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure1,691Cash and equivalents, Q1 FY2026, at 2026-03-31$1.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure196Cash and equivalents, Q2 FY2026, at 2026-06-30$196.3k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure
Current assets$k7,907Current assets, Q3 FY2023, at 2023-09-30$7.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0001493152-23-040472.Report this figure5,632Current assets, FY2023, at 2023-12-31$5.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-20, accession 0001641172-25-000070.Report this figure9,800Current assets, Q1 FY2024, at 2024-03-31$9.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-10, accession 0001493152-24-018648.Report this figure7,478Current assets, Q2 FY2024, at 2024-06-30$7.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001493152-24-031622.Report this figure4,838Current assets, Q3 FY2024, at 2024-09-30$4.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figure1,879Current assets, FY2024, at 2024-12-31$1.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-18, accession 0001493152-26-011204.Report this figure3,758Current assets, Q1 FY2025, at 2025-03-31$3.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001641172-25-009252.Report this figure7,154Current assets, Q2 FY2025, at 2025-06-30$7.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001493152-25-011685.Report this figure6,587Current assets, Q3 FY2025, at 2025-09-30$6.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure5,671Current assets, FY2025, at 2025-12-31$5.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure1,938Current assets, Q1 FY2026, at 2026-03-31$1.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure2,066Current assets, Q2 FY2026, at 2026-06-30$2.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure
Total assets$k8,083Total assets, Q3 FY2023, at 2023-09-30$8.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0001493152-23-040472.Report this figure5,787Total assets, FY2023, at 2023-12-31$5.8m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-20, accession 0001641172-25-000070.Report this figure9,945Total assets, Q1 FY2024, at 2024-03-31$9.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-10, accession 0001493152-24-018648.Report this figure7,601Total assets, Q2 FY2024, at 2024-06-30$7.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001493152-24-031622.Report this figure4,942Total assets, Q3 FY2024, at 2024-09-30$4.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figure3,229Total assets, FY2024, at 2024-12-31$3.2m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-18, accession 0001493152-26-011204.Report this figure4,810Total assets, Q1 FY2025, at 2025-03-31$4.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001641172-25-009252.Report this figure8,182Total assets, Q2 FY2025, at 2025-06-30$8.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001493152-25-011685.Report this figure7,585Total assets, Q3 FY2025, at 2025-09-30$7.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure7,814Total assets, FY2025, at 2025-12-31$7.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure4,521Total assets, Q1 FY2026, at 2026-03-31$4.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure2,070Total assets, Q2 FY2026, at 2026-06-30$2.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure
Current liabilities$k826Current liabilities, Q3 FY2023, at 2023-09-30$826.1k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0001493152-23-040472.Report this figure731Current liabilities, FY2023, at 2023-12-31$730.6k. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-20, accession 0001641172-25-000070.Report this figure1,011Current liabilities, Q1 FY2024, at 2024-03-31$1.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-10, accession 0001493152-24-018648.Report this figure1,552Current liabilities, Q2 FY2024, at 2024-06-30$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001493152-24-031622.Report this figure1,219Current liabilities, Q3 FY2024, at 2024-09-30$1.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figure1,533Current liabilities, FY2024, at 2024-12-31$1.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-18, accession 0001493152-26-011204.Report this figure1,283Current liabilities, Q1 FY2025, at 2025-03-31$1.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001641172-25-009252.Report this figure2,075Current liabilities, Q2 FY2025, at 2025-06-30$2.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001493152-25-011685.Report this figure1,751Current liabilities, Q3 FY2025, at 2025-09-30$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure2,236Current liabilities, FY2025, at 2025-12-31$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure1,980Current liabilities, Q1 FY2026, at 2026-03-31$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure2,387Current liabilities, Q2 FY2026, at 2026-06-30$2.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure
Total liabilities$k915Total liabilities, Q3 FY2023, at 2023-09-30$914.8k. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0001493152-23-040472.Report this figure797Total liabilities, FY2023, at 2023-12-31$797.5k. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-20, accession 0001641172-25-000070.Report this figure1,061Total liabilities, Q1 FY2024, at 2024-03-31$1.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-10, accession 0001493152-24-018648.Report this figure1,577Total liabilities, Q2 FY2024, at 2024-06-30$1.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001493152-24-031622.Report this figure1,221Total liabilities, Q3 FY2024, at 2024-09-30$1.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figure1,533Total liabilities, FY2024, at 2024-12-31$1.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-18, accession 0001493152-26-011204.Report this figure1,283Total liabilities, Q1 FY2025, at 2025-03-31$1.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001641172-25-009252.Report this figure2,075Total liabilities, Q2 FY2025, at 2025-06-30$2.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001493152-25-011685.Report this figure1,751Total liabilities, Q3 FY2025, at 2025-09-30$1.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure2,236Total liabilities, FY2025, at 2025-12-31$2.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure1,980Total liabilities, Q1 FY2026, at 2026-03-31$2.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure2,387Total liabilities, Q2 FY2026, at 2026-06-30$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure
Long-term debt$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$k7,168Shareholders' equity, Q3 FY2023, at 2023-09-30$7.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figure4,989Shareholders' equity, FY2023, at 2023-12-31$5.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-18, accession 0001493152-26-011204.Report this figure8,883Shareholders' equity, Q1 FY2024, at 2024-03-31$8.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure6,024Shareholders' equity, Q2 FY2024, at 2024-06-30$6.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure3,721Shareholders' equity, Q3 FY2024, at 2024-09-30$3.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure1,696Shareholders' equity, FY2024, at 2024-12-31$1.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure3,527Shareholders' equity, Q1 FY2025, at 2025-03-31$3.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure6,107Shareholders' equity, Q2 FY2025, at 2025-06-30$6.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure5,834Shareholders' equity, Q3 FY2025, at 2025-09-30$5.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure5,577Shareholders' equity, FY2025, at 2025-12-31$5.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure2,541Shareholders' equity, Q1 FY2026, at 2026-03-31$2.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure(317)Shareholders' equity, Q2 FY2026, at 2026-06-30−$317.3k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure

Cash flow

Operating cash flow−$2.0m, Q2 FY2026
Capital expenditure$0, Q4 FY2024
Processa Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(1,761)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-10-30, accession 0001493152-24-043058. Derived: 9-month figure less the 6-month figure.Report this figure(2,124)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-20, accession 0001641172-25-000070. Derived: 12-month figure less the 9-month figure.Report this figure(2,049)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001641172-25-009252.Report this figure(3,346)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$3.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001493152-25-011685. Derived: 6-month figure less the 3-month figure.Report this figure(3,603)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001493152-25-021069. Derived: 9-month figure less the 6-month figure.Report this figure(2,248)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001493152-26-011204. Derived: 12-month figure less the 9-month figure.Report this figure(2,730)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$2.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure(2,270)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$2.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001493152-26-038334. Derived: 6-month figure less the 3-month figure.Report this figure(3,484)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001493152-25-021069. Derived: 9-month figure less the 6-month figure.Report this figure(2,901)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001493152-26-011204. Derived: 12-month figure less the 9-month figure.Report this figure(3,591)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure(1,996)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001493152-26-038334. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$knot reported0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0001641172-25-000070. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reported0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0001641172-25-000070. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)2.75m, Q2 FY2026
Processa Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares16.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3016,200,222 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0001493152-23-040472.Report this figure1.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-311,138,573 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-10, accession 0001493152-24-018648.Report this figure1.3Diluted shares (weighted), Q2 FY2023, three months to 2023-06-301,346,808 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001493152-24-031622.Report this figure1.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-301,350,188 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-10-30, accession 0001493152-24-043058.Report this figure2.5Diluted shares (weighted), Q1 FY2024, three months to 2024-03-312,466,523 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001641172-25-009252.Report this figure3.0Diluted shares (weighted), Q2 FY2024, three months to 2024-06-302,983,283 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001493152-25-011685.Report this figure3.3Diluted shares (weighted), Q3 FY2024, three months to 2024-09-303,275,998 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure0.4Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31373,967 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure0.6Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30628,796 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure47.5Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3047,525,522 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001493152-25-021069.Report this figure2.6Diluted shares (weighted), Q1 FY2026, three months to 2026-03-312,623,143 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001493152-26-021721.Report this figure2.8Diluted shares (weighted), Q2 FY2026, three months to 2026-06-302,750,742 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure

Shares outstanding: 2.79mShares outstanding, period not labelled, at 2026-08-072,793,386 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001493152-26-038334.Report this figure at Aug 7, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.